🇺🇸 Fibrogammin P in United States

49 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. No Adverse Event — 8 reports (16.33%)
  2. Abortion Spontaneous — 6 reports (12.24%)
  3. Drug Ineffective — 6 reports (12.24%)
  4. Haemorrhage — 5 reports (10.2%)
  5. Atrial Fibrillation — 4 reports (8.16%)
  6. Congenital Genital Malformation — 4 reports (8.16%)
  7. Factor Xiii Inhibition — 4 reports (8.16%)
  8. Haemoglobin Decreased — 4 reports (8.16%)
  9. Product Use In Unapproved Indication — 4 reports (8.16%)
  10. Pyrexia — 4 reports (8.16%)

Source database →

Frequently asked questions

Is Fibrogammin P approved in United States?

Fibrogammin P does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Fibrogammin P in United States?

Children's Hospital of Orange County is the originator. The local marketing authorisation holder may differ — check the official source linked above.